RecruitingNot ApplicableNCT02502162
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Sponsor
Stanford University
Enrollment
120 participants
Start Date
Jun 1, 2015
Study Type
INTERVENTIONAL
Conditions
Summary
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria4
- Upper and/or lower extremity CRPS
- On stable treatment for 1 month
- CRPS for at least 1 year
- Meet the Budapest criteria for CRPS at time of the study.
Exclusion Criteria3
- Any known allergy to naltrexone or naloxone
- Use of prescription opioid analgesics or illegal opioid use
- Current or planned pregnancy.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLDN
DRUGPlacebo
Sugar pill
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02502162
Related Trials
The Effects of Whirlpool and Contrast Bath in Patients with Complex Regional Pain Syndrome After Distal Radius Fracture
NCT067693731 location
The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
NCT063931012 locations